Reviewing Case Studies to Understand How ADC Design Influences Early-Stage Clinical Outcomes
- Evaluating opportunities for ADCs with novel design to deliver differentiated clinical outcomes
- Reviewing early-stage clinical results from LCB14 to understand the impact of bioconjugation and linker within the HER2 targeting ADC space
- Delving into the early clinical profile of LCB71, a pro-PBD bearing ROR1 targeting ADC, demonstrating differentiated clinical safety and efficacy